Cargando…
The Benefit of Early and Frequent Antitumor Necrosis Factor-Alpha Trough Level Determination in Very Early-Onset Inflammatory Bowel Disease
A patient with infantile-onset Crohn's disease had a partial response to corticosteroid therapy that worsened on its tapering, leading to treatment with antitumor necrosis factor-alpha monoclonal antibody therapy. Infliximab rapidly cleared before administration of the third accelerated inducti...
Autores principales: | Gillmore, Taylor, Jimenez-Rivera, Carolina, Mack, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624466/ https://www.ncbi.nlm.nih.gov/pubmed/37928229 http://dx.doi.org/10.14309/crj.0000000000001197 |
Ejemplares similares
-
Recent Advance in Very Early Onset Inflammatory Bowel Disease
por: Shim, Jung Ok
Publicado: (2019) -
Recent advance in very early-onset inflammatory bowel disease
por: Shim, Jung Ok
Publicado: (2019) -
Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019) -
Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease
por: Dhillon, Sandeep S, et al.
Publicado: (2014) -
Phenotype and outcomes of very early onset and early onset inflammatory bowel diseases in a Montreal pediatric cohort
por: Chapuy, Laurence, et al.
Publicado: (2023)